SAH (Subarachnoid Hemorrhage)NCT06683469
Neutrophil-to-Lymphocyte Ratio in Predicting Outcomes of Patients With Aneurysmal Subarachnoid Hemorrhage in a Tertiary Care Hospital in Nepal
An observational study of SAH (Subarachnoid Hemorrhage), run by Sujan Paudel at 1 site in Nepal.
Trial summary
This study uses Neutrophil-to-Lymphocyte Ratio to Predict Outcomes of Patients with Aneurysmal Subarachnoid Hemorrhage which will be beneficial in taking early decisions for surgery , patient counselling etc Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- SAH (Subarachnoid Hemorrhage)
- How many people
- 51 participants
- Where
- 1 siteNepal
- Study dates
- 10 Jun 2022to 13 Jul 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Patients > 18 years of age, of either genders, ethnicity and location who presented to the emergency department within 72 hours of the onset of symptoms who underwent surgical or interventional treatment for SAH caused by a ruptured intracranial aneurysm
Who may be able to join
- Patients > 18 years of age, of either genders, ethnicity and location who presented to the emergency department within 72 hours of the onset of symptoms who underwent surgical or interventional treatment for SAH caused by a ruptured intracranial aneurysm
Who cannot join
- excluded patients with traumatic SAH, history of infection or stroke within eight weeks, underlying cancer, severe kidney or liver disease, history of auto-immune or hematologic disorder lost to follow-up within three months and individuals declining informed consent.
Trial locations and contacts
1 site in 1 country.
About this study
This study uses Neutrophil-to-Lymphocyte Ratio to Predict Outcomes of Patients with Aneurysmal Subarachnoid Hemorrhage which will be beneficial in taking early decisions for surgery , patient counselling etc
- Conditions
- SAH (Subarachnoid Hemorrhage)
- Medical subject headings
- Subarachnoid Hemorrhage
What is being measured
The primary outcome is the main question the study is designed to answer.
mRS score
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Nov 2024
- Study start10 Jun 2022
- Primary completion10 Apr 2023
- Study completion13 Jul 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SAH (Subarachnoid Hemorrhage)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 51 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sujan Paudel
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Sujan Paudel, Maharajgunj Medical Campus
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06683469
- Sponsor's protocol ID
- MaharajgunjMed
- Status last verified
- Nov 2024
- First submitted
- 8 Nov 2024
- Last updated
- 12 Nov 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Guo Y, Liu J, Zeng H, Cai L, Wang T, Wu X, Yu K, Zheng Y, Chen H, Peng Y, Yu X, Yan F, Cao S, Chen G. Neutrophil to lymphocyte ratio predicting poor outcome after aneurysmal subarachnoid hemorrhage: A retrospective study and updated meta-analysis. Front Immunol. 2022 Aug 9;13:962760. doi: 10.3389/fimmu.2022.962760. eCollection 2022.
PubMed 36016932
Study at a glance
From the registry record, last updated by the sponsor on 12 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Neutrophil-to-Lymphocyte Ratio in Predicting Outcomes of Patients With Aneurysmal Subarachnoid Hemorrhage in a Tertiary Care Hospital in Nepal
- ClinicalTrials.gov ID
- NCT06683469
- Acronym / sponsor ID
- MaharajgunjMed
- Conditions
- SAH (Subarachnoid Hemorrhage)
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 51 participants (actual)
- Lead sponsor
- Sujan PaudelUniversity, hospital or other
- Study start
- 10 Jun 2022 (actual)
- Primary completion
- 10 Apr 2023 (actual)
- Study completion
- 13 Jul 2023 (actual)
- First posted
- 12 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study uses Neutrophil-to-Lymphocyte Ratio to Predict Outcomes of Patients with Aneurysmal Subarachnoid Hemorrhage which will be beneficial in taking early decisions for surgery , patient counselling etc
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Patients > 18 years of age, of either genders, ethnicity and location who presented to the emergency department within 72 hours of the onset of symptoms who underwent surgical or interventional treatment for SAH caused by a ruptured intracranial aneurysm
Key inclusion criteria (1 listed)
- Patients > 18 years of age, of either genders, ethnicity and location who presented to the emergency department within 72 hours of the onset of symptoms who underwent surgical or interventional treatment for SAH caused by a ruptured intracranial aneurysm
Key exclusion criteria (1 listed)
- excluded patients with traumatic SAH, history of infection or stroke within eight weeks, underlying cancer, severe kidney or liver disease, history of auto-immune or hematologic disorder lost to follow-up within three months and individuals declining informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
mRS score
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Nov 2024.
- Results publication: PubMed 36016932Guo Y, Liu J, Zeng H, Cai L, Wang T, Wu X, Yu K, Zheng Y, Chen H, Peng Y, Yu X, Yan F, Cao S, Chen G. Neutrophil to lymphocyte ratio predicting poor outcome after aneurysmal subarachnoid hemorrhage: A retrospective study and updated meta-analysis. Front Immunol. 2022 Aug 9;13:962760. doi: 10.3389/fimmu.2022.962760. eCollection 2022.
- Individual participant dataSharing planned: Undecided
Related trials for SAH (Subarachnoid Hemorrhage)
Not yet recruitingPhase 3
TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study
Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia
Not yet recruitingObservational study
Continuous Assessment of Brain Blood Perfusion in Subarachnoid Hemorrhage Patients Using Near-Infrared Spectroscopy (NIRS)
Subarachnoid Hemorrhage, Aneurysmal
RecruitingObservational study
AI-based Algorithm Development for Improved Diagnostics in the Intensive Care and Acute Stroke Setting Using Electroencephalography
Hemorrhagic Stroke, Intracerebral, Subarachnoid Haemorrhage (SAH)
Not yet recruitingObservational study
Decompressive Craniectomy After Aneurysmal Subarachnoid Hemorrhage (DECIDE-SAH)
Aneurysmal Subarachnoid Hemorrhage
RecruitingObservational study
Metabolomics in Subarachnoid Hemorrhage
Subarachnoid Haemorrhage (SAH), Delayed Cerebral Ischemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of SAH (Subarachnoid Hemorrhage), run by Sujan Paudel at 1 site in Nepal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Nepal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
mRS score (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06683469, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Nov 2024.